GLUCOSAMINE/CHONDROITIN and PHYSICAL THERAPY EFFECTS ON OLDER POPULATION WITH KNEE OSTEOARTHRITIS

April 4, 2022 updated by: Muhammad salman, PT

EFFECTS OF COMBINED GLUCOSAMINE/CHONDROITIN WITH STRUCTURED PHYSICAL THERAPY PROGRAM ON KNEE OSTEOARTHRITIS: A RANDOMIZED CONTROL TRAIL

to see the effect of glucosamine chondratin sulfate with and without physiotherapy in knee osteoarthritis

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

it is a randomized control trail to evaluate the effectiveness of glucosamine chondratin sulfate alone and in combination with physiotherapy on knee osteoarthritis

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Rawalpindi, Punjab, Pakistan, 46030
        • Muhammad Umar

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age > 50 years with radiographic evidence of mild to moderate knee OA (Kellgren Lawrence grade II & III 20) who met the ACR clinical 21,
  • radiographic classification criteria or confirmation of mild to moderate radiographic evidence of knee OA from a personal physician
  • not currently participating in another intervention study

Exclusion Criteria:

  • dementia (Mini-Mental State Examination [MMSE]< 24)
  • active cancer other than skin cancer
  • anemia (participants with an hematocrit (HCT)< 32 (or a hemoglobin below10) were excluded due to possible inability to adequately exercise or the increased potential for increased risk for serious adverse cardiovascular events)
  • severe renal insufficiency (serum creat> 2)
  • hepatic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: control group
chondritin sulfate 1500/1200mg
Other: Glucosamine Chondroitin
control group
Experimental: experimental group
chondritin sulfate plus physiotherapy
Combination product: glucosamine chondritin & Physiotherapy
experimental group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
WOMAC
Time Frame: 6 months
higher score means worst patient condition and lower score means better
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SF-36
Time Frame: 6 months
higher score means better patient condition and lower score means worst
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Muhammad salman, PT

Investigators

  • Principal Investigator: MUHAMMAD UMAR, The Physiotherapy Clinic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 26, 2021

Primary Completion (Actual)

March 25, 2022

Study Completion (Actual)

March 25, 2022

Study Registration Dates

First Submitted

March 26, 2022

First Submitted That Met QC Criteria

April 4, 2022

First Posted (Actual)

April 11, 2022

Study Record Updates

Last Update Posted (Actual)

April 11, 2022

Last Update Submitted That Met QC Criteria

April 4, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 333 (Other Grant/Funding Number: Florida Department of Health)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

Clinical Trials on Glucosamine Chondroitin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe